Literature DB >> 12651811

Catecholamine-synthesizing enzymes in carcinoid tumors and pheochromocytomas.

Wim G Meijer1, Sjef C V M Copray, Harry Hollema, Ido P Kema, Nynke Zwart, Ietje Mantingh-Otter, Thera P Links, Pax H B Willemse, Elisabeth G E de Vries.   

Abstract

BACKGROUND: Serotonin is the principal endocrine product of carcinoid tumors, but simultaneously increased production of catecholamines has been described in these tumors. As it is not clear whether these tumors contain specific enzymes for catecholamine synthesis, we aimed to detect catecholamine-synthesizing enzymes [tyrosine hydroxylase (TH), dopamine-beta-hydroxylase (DBH), and phenylethanolamine-N-methyltransferase (PNMT)] in midgut carcinoid tumors and pheochromocytoma and to correlate enzyme expression to serotonin production as well as catecholamines and metabolites excreted in urine.
METHODS: Paraffin-embedded tumor specimens from 21 midgut carcinoid patients and 20 pheochromocytoma patients (10 sporadic and 10 MEN type IIa-related tumors) were stained for TH, DBH, and PNMT, using a three-step biotin-avidin-peroxidase method.
RESULTS: TH was demonstrated in 9 (43%) of 21 carcinoids and in all (100%) of 20 pheochromocytomas, DBH in 8 (38%) carcinoids and in 15 (75%) pheochromocytomas, and PNMT in 7 (33%) carcinoids and in 13 (65%) pheochromocytomas. Increased urinary excretion of catecholamines and metabolites was observed in 10 (48%) carcinoid patients and in all pheochromocytoma patients. No clinically relevant association between enzyme expression and urinary excretion of catecholamines and metabolites was found.
CONCLUSIONS: Catecholamine-synthesizing enzymes are present in many carcinoid tumors. This finding possibly indicates the existence of a catecholamine-synthesizing pathway in carcinoids similar to that found in pheochromocytoma.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12651811     DOI: 10.1373/49.4.586

Source DB:  PubMed          Journal:  Clin Chem        ISSN: 0009-9147            Impact factor:   8.327


  13 in total

1.  Catecholamine-Synthesizing Enzymes in Pheochromocytoma and Extraadrenal Paraganglioma.

Authors:  Sachiko Konosu-Fukaya; Kei Omata; Yuta Tezuka; Yoshikiyo Ono; Yayoi Aoyama; Fumitoshi Satoh; Fumiyoshi Fujishima; Hironobu Sasano; Yasuhiro Nakamura
Journal:  Endocr Pathol       Date:  2018-12       Impact factor: 3.943

2.  Noradrenalin-secreting retroperitoneal schwannoma resected by hand-assisted laparoscopic surgery: report of a case.

Authors:  Tomohide Hori; Kentaro Yamagiwa; Shintaro Yagi; Taku Iida; Kentaro Taniguchi; Chiduru Yamamoto; Yukitsuna Eshita; Yuji Kozuka; Haruyuki Takaki; Takuma Kato; Kanako Saito; Mie Torii; Syuji Isaji; Shinji Uemoto
Journal:  Surg Today       Date:  2006-12-25       Impact factor: 2.549

3.  Biochemically silent abdominal paragangliomas in patients with mutations in the succinate dehydrogenase subunit B gene.

Authors:  Henri J L M Timmers; Karel Pacak; Thanh T Huynh; Mones Abu-Asab; Maria Tsokos; Maria J Merino; Bora E Baysal; Karen T Adams; Graeme Eisenhofer
Journal:  J Clin Endocrinol Metab       Date:  2008-10-07       Impact factor: 5.958

4.  Encapsulated pheochromocytoma cells secrete potent noncatecholamine factors.

Authors:  Hector R Mobine; George C Engelmayr; Nelson Moussazadeh; Tayyba R Anwar; Lisa E Freed; Elazer R Edelman
Journal:  Tissue Eng Part A       Date:  2009-07       Impact factor: 3.845

5.  Increased local dopamine secretion has growth-promoting effects in cholangiocarcinoma.

Authors:  Monique Coufal; Pietro Invernizzi; Eugenio Gaudio; Francesca Bernuzzi; Gabriel A Frampton; Paolo Onori; Antonio Franchitto; Guido Carpino; Jonathan C Ramirez; Domenico Alvaro; Marco Marzioni; Guido Battisti; Antonio Benedetti; Sharon DeMorrow
Journal:  Int J Cancer       Date:  2010-05-01       Impact factor: 7.396

6.  Pheochromocytoma-induced cardiomyopathy is modulated by the synergistic effects of cell-secreted factors.

Authors:  Hector R Mobine; Aaron B Baker; Libin Wang; Hiroko Wakimoto; Kurt C Jacobsen; Christine E Seidman; J G Seidman; Elazer R Edelman
Journal:  Circ Heart Fail       Date:  2009-02-10       Impact factor: 8.790

Review 7.  Molecular and therapeutic advances in the diagnosis and management of malignant pheochromocytomas and paragangliomas.

Authors:  Aoife J Lowery; Siun Walsh; Enda W McDermott; Ruth S Prichard
Journal:  Oncologist       Date:  2013-04-10

8.  Immunohistochemical distinction of paragangliomas from epithelial neuroendocrine tumors-gangliocytic duodenal and cauda equina paragangliomas align with epithelial neuroendocrine tumors.

Authors:  Divya Mamilla; Irena Manukyan; Patricia A Fetsch; Karel Pacak; Markku Miettinen
Journal:  Hum Pathol       Date:  2020-07-12       Impact factor: 3.466

9.  Total 18F-dopa PET tumour uptake reflects metabolic endocrine tumour activity in patients with a carcinoid tumour.

Authors:  Helle-Brit Fiebrich; Johan R de Jong; Ido P Kema; Klaas Pieter Koopmans; Wim Sluiter; Rudi A J O Dierckx; Annemiek M Walenkamp; Thera P Links; Adrienne H Brouwers; Elisabeth G E de Vries
Journal:  Eur J Nucl Med Mol Imaging       Date:  2011-06-23       Impact factor: 9.236

10.  Management of sub-5 mm rectal carcinoids with lymph node metastases.

Authors:  James Wei Tatt Toh; Christopher Henderson; Takako Eva Yabe; Evonne Ong; Pierre Chapuis; Les Bokey
Journal:  Gastroenterol Rep (Oxf)       Date:  2014-10-22
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.